Literature DB >> 25796139

Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.

Stephanie J Lee1, Daniel Wolff2, Carrie Kitko3, John Koreth4, Yoshihiro Inamoto5, Madan Jagasia6, Joseph Pidala7, Attilio Olivieri8, Paul J Martin1, Donna Przepiorka9, Iskra Pusic10, Fiona Dignan11, Sandra A Mitchell12, Anita Lawitschka13, David Jacobsohn14, Anne M Hall1, Mary E D Flowers1, Kirk R Schultz15, Georgia Vogelsang16, Steven Pavletic17.   

Abstract

In 2005, the National Institutes of Health (NIH) Chronic Graft-versus-Host Disease (GVHD) Consensus Response Criteria Working Group recommended several measures to document serial evaluations of chronic GVHD organ involvement. Provisional definitions of complete response, partial response, and progression were proposed for each organ and for overall outcome. Based on publications over the last 9 years, the 2014 Working Group has updated its recommendations for measures and interpretation of organ and overall responses. Major changes include elimination of several clinical parameters from the determination of response, updates to or addition of new organ scales to assess response, and the recognition that progression excludes minimal, clinically insignificant worsening that does not usually warrant a change in therapy. The response definitions have been revised to reflect these changes and are expected to enhance reliability and practical utility of these measures in clinical trials. Clarification is provided about response assessment after the addition of topical or organ-targeted treatment. Ancillary measures are strongly encouraged in clinical trials. Areas suggested for additional research include criteria to identify irreversible organ damage and validation of the modified response criteria, including in the pediatric population. Published by Elsevier Inc.

Entities:  

Keywords:  Allogeneic hematopoietic cell transplantation; Chronic graft-versus-host disease; Consensus; Guidelines; Response criteria

Mesh:

Substances:

Year:  2015        PMID: 25796139      PMCID: PMC4744804          DOI: 10.1016/j.bbmt.2015.02.025

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  111 in total

1.  The 6-minute walk test: normal values for children of 4-11 years of age.

Authors:  A E Lammers; A A Hislop; Y Flynn; S G Haworth
Journal:  Arch Dis Child       Date:  2007-08-03       Impact factor: 3.791

2.  Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation.

Authors:  Matin M Imanguli; Jane C Atkinson; Sandra A Mitchell; Daniele N Avila; Rachel J Bishop; Edward W Cowen; Manuel B Datiles; Frances T Hakim; David E Kleiner; Michael C Krumlauf; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-28       Impact factor: 5.742

3.  Validation of the National Institutes of Health (NIH) scale for oral chronic graft-versus-host disease (cGVHD).

Authors:  Sharon Elad; Itai Zeevi; Reuven Or; Igor B Resnick; Lilian Dray; Michael Y Shapira
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-03       Impact factor: 5.742

4.  Health-related quality of life in pediatric bone marrow transplant survivors: according to whom?

Authors:  S K Parsons; S E Barlow; S L Levy; S E Supran; S H Kaplan
Journal:  Int J Cancer Suppl       Date:  1999

5.  Spirometry in preschool children: time has come for new reference values.

Authors:  H Kalhoff; R Breidenbach; H J Smith; W Marek
Journal:  J Physiol Pharmacol       Date:  2009-11       Impact factor: 3.011

6.  Oral chronic graft-versus-host disease scoring using the NIH consensus criteria.

Authors:  Nathaniel S Treister; Kristen Stevenson; Haesook Kim; Sook-Bin Woo; Robert Soiffer; Corey Cutler
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-17       Impact factor: 5.742

7.  Lung function and long-term complications after allogeneic hematopoietic cell transplant.

Authors:  Eric C Walter; Mauricio Orozco-Levi; Alba Ramirez-Sarmiento; Afonso Vigorito; Paulo V Campregher; Paul J Martin; Mary E Flowers; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-17       Impact factor: 5.742

8.  Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD).

Authors:  S A Mitchell; N Kline Leidy; K H Mooney; W N Dudley; S L Beck; P C LaStayo; E W Cowen; P Palit; L E Comis; M C Krumlauf; D N Avila; N Atlam; D H Fowler; S Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2009-09-28       Impact factor: 5.483

9.  Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation.

Authors:  Pamela Stratton; Maria L Turner; Richard Childs; John Barrett; Michael Bishop; Alan S Wayne; Steven Pavletic
Journal:  Obstet Gynecol       Date:  2007-11       Impact factor: 7.661

10.  What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D.

Authors:  Stephen J Walters; John E Brazier
Journal:  Health Qual Life Outcomes       Date:  2003-04-11       Impact factor: 3.186

View more
  95 in total

Review 1.  Oral Complications of Chronic Graft-Versus-Host Disease.

Authors:  Jane M Fall-Dickson; Steven Z Pavletic; Jacqueline W Mays; Mark M Schubert
Journal:  J Natl Cancer Inst Monogr       Date:  2019-08-01

2.  Translation, Cross-Cultural Adaptation, and Validation of the Lee Chronic Graft-versus-Host Disease Symptom Scale in a Brazilian Population.

Authors:  Clarissa Vasconcellos de Souza; Afonso Celso Vigorito; Eliana C M Miranda; Celso Garcia; Vergílio Antonio Rensi Colturato; Marcos Augusto Mauad; Maria Cláudia Rodrigues Moreira; Luis Fernando da Silva Bouzas; Simone Lermontov; Nelson Hamerschlak; Morgani Rodrigues; Jose Carlos de Almeida Barros; Ricardo Chiattone; Stephanie J Lee; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-04       Impact factor: 5.742

Review 3.  How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

Authors:  Kirsten M Williams
Journal:  Blood       Date:  2016-11-16       Impact factor: 22.113

Review 4.  Cytokine mediators of chronic graft-versus-host disease.

Authors:  Kelli Pa MacDonald; Bruce R Blazar; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

5.  Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.

Authors:  Emily C Merkel; Sandra A Mitchell; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2016-01-02       Impact factor: 5.742

Review 6.  How I treat refractory chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Adela R Cardones; Keith M Sullivan
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

7.  Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.

Authors:  Kirsten M Williams; Guang-Shing Cheng; Iskra Pusic; Madan Jagasia; Linda Burns; Vincent T Ho; Joseph Pidala; Jeanne Palmer; Laura Johnston; Sebastian Mayer; Jason W Chien; David A Jacobsohn; Steven Z Pavletic; Paul J Martin; Barry E Storer; Yoshihiro Inamoto; Xiaoyu Chai; Mary E D Flowers; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-22       Impact factor: 5.742

8.  Autologous blood as a source of platelet gel for the effective and safe treatment of oral chronic graft-versus-host disease.

Authors:  Ines Bojanic; Marinka Mravak Stipetic; Drazen Pulanic; Lana Desnica; Sanja Mazic; Branka Golubic Cepulic; Ranka Serventi Seiwerth; Radovan Vrhovac; Damir Nemet; Steven Z Pavletic
Journal:  Transfusion       Date:  2018-03-14       Impact factor: 3.157

Review 9.  Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.

Authors:  Yoshihiro Inamoto; Nuria Valdés-Sanz; Yoko Ogawa; Monica Alves; Luigi Berchicci; John Galvin; Hildegard Greinix; Gregory A Hale; Biljana Horn; Debra Kelly; Hien Liu; Scott Rowley; Helene Schoemans; Ami Shah; Maria Teresa Lupo Stanghellini; Vaibhav Agrawal; Ibrahim Ahmed; Asim Ali; Neel Bhatt; Michael Byrne; Saurabh Chhabra; Zachariah DeFilipp; Kristina Fahnehjelm; Nosha Farhadfar; Erich Horn; Catherine Lee; Sunita Nathan; Olaf Penack; Pinki Prasad; Seth Rotz; Alicia Rovó; Jean Yared; Steven Pavletic; Grzegorz W Basak; Minoo Battiwalla; Rafael Duarte; Bipin N Savani; Mary E D Flowers; Bronwen E Shaw; Igor Petriček
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-24       Impact factor: 5.742

10.  Non-invasive measurement of sclerosis in cutaneous cGVHD patients with the handheld device Myoton: a cross-sectional study.

Authors:  Fuyao Chen; Laura E Dellalana; Jocelyn S Gandelman; Arved Vain; Madan H Jagasia; Eric R Tkaczyk
Journal:  Bone Marrow Transplant       Date:  2018-10-04       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.